GRAIL Inc(GRAL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -9.75 | Insider Own | 5.62% | Shs Outstand | 44.7M | Perf Week | 19.06% |
| Market Cap | 7.05B | Forward P/E | - | EPS next Y | -7.61% | Insider Trans | -4.98% | Shs Float | 42.2M | Perf Month | 15.6% |
| Enterprise Value | 6.28B | PEG | - | EPS next Q | -2.45 | Inst Own | 86.22% | Short Float | 19.39% | Perf Quarter | 121.93% |
| Income | -0.39B | P/S | 42.67 | EPS this Y | 14.89% | Inst Trans | 5.4% | Short Ratio | 7.95 | Perf Half Y | 217.73% |
| Sales | 0.17B | P/B | 2.77 | EPS next 5Y | 4.45% | ROA | -14.12% | Short Interest | 8.17M | Perf YTD | 84.46% |
| Book/sh | 56.93 | P/C | 8.18 | EPS past 3/5Y | 60.02% -41.05% | ROE | -16.12% | 52W High | -5.16% ($166.48) | Perf Year | 82.82% |
| Cash/sh | 19.29 | P/FCF | - | Sales past 3/5Y | 38.37% - | ROIC | -14.93% | 52W Low | 280.43% ($41.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 24.6% | Gross Margin | -36.99% | Volatility(W/M) | 8.33% 8.6% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 38.01 | Sales Y/Y TTM | 23.07% | Oper. Margin | -323.02% | ATR (14) | 10.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.74 | EPS Q/Q | 19.7% | Profit Margin | -236.95% | RSI (14) | 68.41 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.95 | Sales Q/Q | 25.72% | SMA20 | 15.59% ($136.59) | Beta | 2.84 | Target Price | $132.56 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/4 | SMA50 | 45.88% ($108.23) | Rel Volume | 1.12 | Prev Close | $150.61 |
| Employees | 910 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 3.6% 5.42% | SMA200 | 103.54% ($77.57) | Avg Volume(3M) | 1.03M | Price | $157.88 |
| IPO | 2024/6/12 | Option/Short | Yes/Yes | Trades | 16196 | Volume | 1,151,788 | Change | 4.83% |
A US diagnostics company that develops and commercializes multi-cancer early detection tests. It develops and commercializes blood-based multi-cancer early detection tests, providing exposure to demand for early cancer detection and test adoption. The company operates in the multi-cancer early detection space.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded about as much as usual. That is 112% of its average volume.
Next earnings report: November 4
6 days to go.
GRAL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +14.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,267. Peers typically go for $458.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is negative
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 86.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #18 of 44 in the industry
Based on market cap of $7B.
FAQ
What kind of company is GRAL?
GRAL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of GRAL?
The market cap of GRAL is approximately $7.1B, ranking 1,128 within its sector.
What is the 52-week high and low for GRAL?
GRAL has recorded a 52-week high of $166.48 and a low of $41.50.
